Collegium Pharmaceutical (COLL) News Today

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares are rising after the company reported strong second-quarter results, beat analyst estimates, raised its full-year outlook and unveiled a new share buyback program.

• Positive Sentiment: Second-quarter net revenue jumped 29% year-over-year to $188.0 million, driven by record Jornay PM® sales of $32.6 million and a 23% increase in prescriptions. GlobeNewswire Release
• Positive Sentiment: Raised full-year 2025 net revenue guidance to $745 million–$760 million (above prior consensus of ~$744.3 million) and adjusted EBITDA guidance to $440 million–$455 million. MSN: Guidance Boost
• Positive Sentiment: Reported Q2 earnings of $1.68 per share, beating the Zacks consensus of $1.62, with revenues surpassing estimates—driving a double-digit stock jump. Zacks: Earnings & Revenues Beat
• Positive Sentiment: Board authorized a $150 million share repurchase program, signaling confidence in the business and commitment to shareholder returns. GlobeNewswire Release
• Neutral Sentiment: Published the full Q2 2025 earnings call transcript for detailed management commentary. InsiderMonkey Transcript
• Neutral Sentiment: Released the Q2 results presentation deck outlining operational and financial metrics. Seeking Alpha Presentation
• Neutral Sentiment: Analysts detailed how key Q2 metrics compare with Wall Street estimates and year-ago figures. Zacks: Key Metrics Analysis